Sep 2026· Bone Marrow Transplantation· 1 citation· 52 references
Medicine
TL;DR
This review summarizes the current landscape of POC CAR T-cell manufacturing, emphasizing clinical outcomes, economic sustainability, and regulatory considerations, and discusses emerging technologies, including allogeneic CAR T-cell platforms, artificial intelligence-driven manufacturing, and in vivo gene editing, that may democratize global access.
This model advocates for decentralized, modular cleanroom facilities that integrate fully closed automated manufacturing platforms with risk-based quality management systems and emphasizes the strategic implementation of artificial intelligence (AI) and digital health tools—such as electronic batch records and predicti...
S. Cabrera-Salcedo, L. Parra-Lara, Mónica Fernandes-Pineda et al.· Frontiers in Public Health· 0 citations
Relapses occurring within 2 to 3 months correlated with loss of detectable CAR-NK cells, highlighting limited in vivo persistence as a principal barrier to durable response.
Kun Lu, Mei-Lian Cai, Jing Li et al.· International journal of hem...· 0 citations
While chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematological malignancies, there are significant hurdles to overcome, such as antigen escape, T-cell exhaustion, limited persistence in the body, severe toxicities, manufacturing complexity, high costs, and low effectiveness in...
Faizan-e-Mustaffa, Muhammad Shahbaz Aslam, Muhammad Junaid· Journal of the Egyptian Nati...· 0 citations
The main delivery platforms under clinical investigation are described, focusing on lentiviral vectors and lipid nanoparticles, and their differences in terms of mechanisms of action, associated risks, and optimization strategies are discussed.
François Vilcot, Carole-Anne Brugère, Jaime Fuentealba et al.· Bulletin du Cancer· 0 citations
Although still in its infancy, in vivo genetic engineering shows promise for CAR T cell therapy in a wide range of cancer patients and has the potential to reprogram patients’ immunity in autoimmunity, chronic infections, and regenerative medicine.
Markus Barden, D. Harrer, Hinrich Abken· Expert Opinion on Biological...· 0 citations
The clinical lessons learned from the now substantial experience with commercial CAR T cells and clinical trials are summarized and three waves shaping next-generation development are discussed: multi-engineered and logic-gated CAR T cells, rational combination strategies, and in vivo CAR T cell generation.
D. Usta, Crystal L. Mackall· Cancer Cell· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.